

JITENDRA A PATEL & CO.
CHARTERED ACCOUNTANTS
201, RUSHIKA COMPLEX,
NR. DINESH HALL, AHMEDABAD - 380009

TO,
THE MEMBERS,
MECVIZ ENDOSCOPY (I) PRIVATE LIMITED

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of Mecviz Endoscopy (I) Private Limited ("the Company"), which comprise the balance sheet as at 31st March 2021, and the statement of Profit and Loss and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, and profit/loss and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an private company



Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report, Business Responsibility Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibility of Management for Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- > Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control
- > Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls
- > Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- > Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern
- > Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

- 1 As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013 is not Applicable to this Company.



2 As required by Section 143 (3) of the Act, we report that:

- a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors as on 31st March, 2019 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2019 from being appointed as a director in terms of Section 164 (2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure - A".
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - > The Company does not have any pending litigations which would impact its financial position.
 - > The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - > There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

Place : AHMEDABAD

Date : 06.09.2021



FOR JITENDRA A. PATEL & CO.

CHARTERED ACCOUNTANTS

Jitendra A Patel

(JITENDRA A. PATEL)

PROPRIETOR

M.NO:033543

FRN : 104283W

UDIN: 21033543AAAAGR4351

“Annexure A” to the Independent Auditor’s Report of even date on the Standalone Financial Statements of Mecviz Endoscopy (I) Pvt Ltd.

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of Mecviz Endoscopy (I) Private Limited (“the Company”) as of March 31, 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on “the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.



Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Place : AHMEDABAD

Date : 06.09.2021



FOR, JITENDRA A. PATEL & CO.

CHARTERED ACCOUNTANTS

Jitendra A. Patel

(JITENDRA A. PATEL)

PROPRIETOR

M.NO:033543

FRN : 104283W

UDIN: 21033543AAAAGR4351

MECVIZ ENDOSCOPY (I) PRIVATE LIMITED

BALANCE SHEET AS AT 31ST MARCH, 2021

Particulars		Note No.	31.03.2021	31.03.2020
A	EQUITY AND LIABILITIES			
1	Shareholders' funds			
	(a) Share capital	2.01	500,000	500,000
	(b) Reserves and surplus	2.02	(326,074)	(373,138)
	(c) Money received against share warrants		-	-
			173,926	126,862
2	Share application money pending allotment		-	-
3	Non-current liabilities			
	(a) Long-term borrowings	2.03	-	6,460,598
	(b) Deferred tax liabilities (net)		-	-
	(c) Other long-term liabilities		-	-
	(d) Long-term provisions		-	-
			-	6,460,598
	(a) Short-term borrowings		-	-
	(b) Trade payables	2.04	12,000	-
	(c) Other current liabilities	2.05	673,208	5,000
	(d) Short-term provisions		-	-
			685,208	5,000
	TOTAL		859,134	6,592,460
B	ASSETS			
1	Non-current assets			
	(a) Plant, Property and Equipments			
	(i) Tangible Assets		-	-
	(ii) Intangible Assets		-	-
	(iii) Capital work-in-progress		-	-
	(iv) Intangible assets under Development		-	-
			-	-
	(b) Non-current investments		-	-
	(c) Long-term loans and advances	2.06	86,631	86,631
	(d) Other non-current assets		-	-
	(e) Differed tax asset(net)		119,940	121,614
			206,571	208,245
2	Current assets			
	(a) Current investments		-	-
	(b) Inventories	2.07	-	5,288,212
	(c) Trade receivables	2.08	433,354	876,500
	(d) Cash and cash equivalents	2.09	110,776	111,070
	(e) Short-term loans and advances	2.10	108,433	108,433
	(f) Other current assets	2.11	-	-
			652,563	6,384,215
	TOTAL		859,134	6,592,460
Significant Accounting policies and Notes Forming Part of Accounts				

FOR, JITENDRA A. PATEL & CO
Chartered Accountants

Jitendra A. Patel
(JITENDRA A. PATEL)
PROPRIETOR
FRN: 104283W
UDIN: 21033543AAAAAGR4351



For and on behalf of board

Lawrence
DIRECTOR
DIN : 03056083

Prakash
DIRECTOR
DIN : 03071549

Place : AHMEDABAD
Date : 06.09.2021

Place : AHMEDABAD
Date : 06.09.2021

MECVIZ ENDOSCOPY (I) PRIVATE LIMITED

Cashflow Statement For The Year Ended on 31st March, 2021

Particulars	31.03.2021	31.03.2020
A. Cash Flow From Operating Activities :		
Net Profit after tax and Extra Ordinary Items	47,064	(13,853)
Adjustment for : Tax Provision	-	-
Depreciation	-	-
Deferred Tax Expense	1,674	(4,764)
Add: Interest paid	-	-
Less: Interest Received	-	-
Operating profit before Working Capital Changes	48,738	(18,617)
Adjustments for,		
Debtors	443,146	-
Inventories	5,288,212	-
Loans & Advances and Other Current Assets	-	-
Trade Payables	12,000	(78,727)
Other Current Liabilities and Provisions	668,208	4,153
Less : Tax Paid	-	-
Cash Generated From Operations	6,460,304	(93,191)
B. Cash Flow From Investing Activities :		
Sale of Fixed Asset	-	-
Purchase of Fixed Assets	-	-
Interest Received	-	-
Purchase of investments	-	-
Sale of Investments	-	-
Loans & Advances, Deposits (asset)	-	(6,108)
Net Cash Out Flow From Investing Activities	-	(6,108)
C. Cash Flow From Financing Activities :		
Issue of Equity Share Capital	-	-
Increase in Share Application money	-	-
Repayment of Share Application Money	-	-
Unsecured Loan from Relative	(6,460,598)	-
Secured Loan	-	-
Dividend Paid	-	-
Dividend Distribution Tax	-	-
Interest Paid	-	-
Loans Repaid	-	-
Net Cash Out Flow From Financing Activities	(6,460,598)	-
Net Cash flow from all activities(A+B+C)	(294)	(99,299)
Opening Balance of Cash and Cash Equivalent	111,070	162,974
Closing Balance of Cash and Cash Equivalent	110,776	111,070
Net Decrease in Cash & Cash Equivalents	(294)	(51,904)

FOR, JITENDRA A. PATEL & CO.
Chartered Accountants

Jitendra A. Patel
(JITENDRA A. PATEL)
PROPRIETOR
FRN: 104283W
UDIN: 21033543AAAAGR4351



For and on behalf of board

Kamubhai B. Shah
DIRECTOR
DIN : 03071549

Place : AHMEDABAD
Date : 06.09.2021

Place : AHMEDABAD
Date : 06.09.2021

MECVIZ ENDOSCOPY (I) PRIVATE LIMITED
Statement of Profit and Loss for the year ended 31st March, 2021

Particulars		Note No.	31.03.2021	31.03.2020
			Amount	Amount
A	CONTINUING OPERATIONS			
1	Revenue from operations (gross)	2.12	5,426,416	-
2	Other income	2.13	1	-
3	Total revenue (1+2)		5,426,417	-
4	Expenses			
	(a) Cost of materials consumed		-	-
	(b) Purchases of stock-in-trade	2.14	-	-
	(c) Changes in inventories of finished goods, Wip and stock-in-trade	2.15	5,288,212	-
	(d) Employee benefits expense		-	-
	(e) Finance costs	2.16	260	117
	(f) Depreciation and amortisation expense		-	-
	(g) Other expenses	2.17	89,207	18,500
	Total expenses		5,377,679	18,617
5	Profit / (Loss) before exceptional and extraordinary items and tax(3 - 4)		48,738	(18,617)
6	Exceptional items		-	-
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)		48,738	(18,617)
8	Extraordinary items		-	-
9	Profit / (Loss) before tax (7 ± 8)		48,738	(18,617)
10	Tax expense:			
	(a) Current tax expense for current year		-	-
	(b) (Less): MAT credit (where applicable)		-	-
	(c) Current tax expense relating to prior years		-	-
	(d) Net current tax expense		-	-
	(e) Deferred tax		1,674	(4,764)
			1,674	(4,764)
11	Profit / (Loss) from continuing operations (9 ± 10)		47,064	(13,853)
B	DISCONTINUING OPERATIONS			
12.i	Profit / (Loss) from discontinuing operations (before tax)		-	-
12.ii	Add / (Less): Tax expense of discontinuing operations		-	-
	(a) on ordinary activities attributable to the discontinuing operations		-	-
	(b) on gain / (loss) on disposal of assets / settlement of liabilities		-	-
			-	-
13	Profit / (Loss) from discontinuing operations (12.i ± 12.ii)		-	-
C	TOTAL OPERATIONS			
14	Profit / (Loss) for the year (11 ± 13)		47,064	(13,853)
15	Earning Per Equity Share	2.18		
	(1) Basic		0.94	(0.28)
	(1) Diluted		0.94	(0.28)
Significant Accounting policies and Notes Forming Part of Accounts		1 & 2		

FOR, JITENDRA A. PATEL & CO

Chartered Accountants

Jitendra A Patel

(JITENDRA A. PATEL)

PROPRIETOR

FRN: 104283W

UDIN: 21033543AAAAAGR4351



For and on behalf of board

Kanubhai B. #

DIRECTOR

DIN : 03056083

DIRECTOR

DIN : 03071549

Place AHMEDABAD

Date : 06.09.2021

Place : AHMEDABAD

Date : 06.09.2021

MECVIZ ENDOSCOPY (I) PRIVATE LIMITED

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2021

2.01 Share Capital

Particulars	31.03.2021	31.03.2020
a) Authorized Capital		
50000 Equity Shares of Rs. 10 each	500,000	500,000
	500,000	500,000
b) Issued, Subscribed & Paid Up Capital.		
Paid up Share Capital by Company		
50000 Equity Shares of Rs. 10 each, Fully Paid up	500,000	500,000
Total	500,000	500,000

The reconciliation of the number of shares outstanding as at 31.03.2021 is set out below

Particulars	31.03.2021	31.03.2020
Number of shares outstanding at the beginning	50000	50000
Add: Shares issued during the year	0	0
Less : Share bought back	0	0
Number of shares outstanding at the end	50000	50000

The details of shareholder holding more than 5% shares as at 31.03.2021 is set out below :


Particulars	No. of Shares as at 31.03.2021	% of Shares held as at 31.03.2021	No. of Shares as at 31.03.2020	% of Shares held as at 31.03.2020
Chetan M Joshi	125000	25.00%	125000	25.00%
Parag S Dixit	50000	10.00%	50000	10.00%
Pravin B Shetty	50000	10.00%	50000	10.00%
Saurabha K.Bhatt	125000	25.00%	125000	25.00%
Suryakant N.Chiplunkar	50000	10.00%	50000	10.00%
Vijay S.Patil	50000	10.00%	50000	10.00%
Vishal D. Chandekar	50000	10.00%	50000	10.00%

2.02 Reserve & Surplus

Particulars	31.03.2021	31.03.2020
a) Surplus (Profit & Loss Account)		
Balance brought forward from previous year	(373138)	(359285)
Less: Tax on Regular Assessment Paid	0	0
Add: Profit for the period	47064	(13853)
Total	(326074)	(373138)

2.03 Long Term Borrowings

Particulars	31.03.2021	31.03.2020
a) Term Loan	-	-
b) Loans & Advances From Directors/Relative & Other Parties	0	6460598
Total	0	6460598



MECVIZ ENDOSCOPY (I) PRIVATE LIMITED

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2021

2.04 Trades Payable

Particulars	31.03.2021	31.03.2020
a) Sundry Creditors for Fixed Assets	-	-
b) Sundry Creditors for Goods	-	-
c) Sundry Creditors for other	12,000	-
Total	12,000	-

2.05 Short term Provisions

Particulars	31.03.2021	31.03.2020
<u>A. Current maturities of long-term debt</u> *	-	-
<u>B. Shortterm Provisions</u>		
a) Provision for Income Tax	-	
b) Unpaid Audit Fees	20,000	5000
c) GST Payable	653208	
Total	673208	5000.00



MECVIZ ENDOSCOPY (I) PRIVATE LIMITED

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2021

2.06 Long Term Loans & Advances

Particulars	31.03.2021	31.03.2020
<u>A. Capital Advances</u>		
a) Secured Considered Goods	-	-
b) Unsecured Considered Goods	-	-
c) Doubtful	-	-
<u>B. Security Deposit</u>		
a) Secured Considered Goods	20,000	20000
b) Unsecured Considered Goods	-	-
c) Doubtful	-	-
<u>C. Loans & Advances to Related Parties</u>	-	-
<u>D. Other Loans & Advances</u>		
a) MAT Credit U/S 115JB	66631	66631
Total	86631	86631

2.07 Inventories

Particulars	31.03.2021	31.03.2020
a) Raw Material	-	-
b) Work-in-Progress	-	-
c) Finished Goods	0	5288212
d) Stores & Spares	-	-
Total	0	5288212

2.08 Trade Receivables

Particulars	31.03.2021	31.03.2020
<u>A. Outstanding for more than six months</u>		
a) Secured, Considered Good :	-	-
b) Unsecured, Considered Good :	433354	876500
c) Doubtful	-	-
B. Others		
a) Secured, Considered Good :	-	-
b) Unsecured, Considered Good :	-	-
c) Doubtful	-	-
Total	433354	876500



MECVIZ ENDOSCOPY (I) PRIVATE LIMITED

Notes Forming Integral Part of the Balance Sheet as at 31st March, 2021

2.09 Cash & Cash Equivalent

Particulars	31.03.2021	31.03.2020
	Amount	Amount
A. Cash-in-Hand		
a) Cash Balance	26259	26259
b) Petty Cash Balance	-	-
Sub Total (A)	26259	26259
B. Bank Balance		
Current Accounts		
a) In current accounts - PUNJAB NATIONAL BANK	84517	84811
Sub Total (B)	84517	84811
Cheques on Hand	-	-
Total [A + B + C]	110776	111070

2.10 Short Terms Loans and Advances

Particulars	31.03.2021	31.03.2020
	Amount	Amount
A. Loans & Advances to related parties		
a) Secured, Considered Good :	-	-
b) Unsecured, Considered Good :	-	-
c) Doubtful	-	-
B. Others		
a) Balance with revenue authorities	-	-
b) loan & Advances to Suppliers	-	-
c) other Advances	-	-
d) TDS Receivable	-	-
e) VAT Receivable	108433	108433
Total	108433	108433

2.11 Other Current Assets

Particulars	31.03.2021	31.03.2020
	Amount	Amount
Miscellaneous Expense	-	-
Total	-	-



MECVIZ ENDOSCOPY (I) PRIVATE LIMITED

Notes Forming Part of the Profit & Loss Accounts as at 31st March, 2021

2.12 Revenue from operations

	Particulars	31.03.2021	31.03.2020
		Amount	Amount
(a)	Sale of products	5426416	-
(b)	Sale of services		-
(c)	Other operating revenues	5426416	-
	<u>Less:</u>		
(d)	GST	-	-
	Total	5,426,416	-

2.13 Other income

	Particulars	31.03.2021	31.03.2020
		Amount	Amount
(a)	Interest income	-	-
(b)	Commission income	-	-
(c)	Net gain on sale of:		
	current investments	-	-
	long-term investments	-	-
(d)	Adjustments to the carrying amount of investments -	-	-
	reversal of reduction in the carrying amount of:		
	current investments	-	-
	long-term investments	-	-
(e)	Net gain on foreign currency transactions and translation	-	-
	(other than considered as finance cost)		
(f)	Discount and Waiver Income	1	-
	Total	1	-



MECVIZ ENDOSCOPY (I) PRIVATE LIMITED

Notes Forming Part of the Statement of Profit & Loss as at 31st March, 2021

2.14 Purchase of traded goods

Particulars	31.03.2021	31.03.2020
	Amount	Amount
Traded Goods	0	0
Other items	0	0
Total	0	0

2.15 Changes in inventories of finished goods, work-in-progress and stock-in-trade


Particulars	31.03.2021	31.03.2020
	Amount	Amount
Inventories at the end of the year:		
Finished goods	-	5288212
Work-in-progress	-	-
Stock-in-trade	-	-
	0	5288212
Inventories at the beginning of the year:		
Finished goods	5288212	5288212
Work-in-progress	-	-
Stock-in-trade	-	-
	5288212	5288212
Net (increase) / decrease	5288212	0

2.16 Finance costs

Particulars	31.03.2021	31.03.2020
	Amount	Amount
(a) Interest expense on:		
(i) Borrowings	-	-
(ii) Trade payables	-	-
(iii) Others		
Interest on delayed payments of TDS	-	-
Interest on delayed payments of CST	-	-
Interest on delayed payments of VAT	-	-
Bank charges	260	117
(b) Other borrowing costs (Unsecured Loan)	-	-
Total	260	117

2.17 Other expenses

Particulars	31.03.2021	31.03.2020
	Amount	Amount
Audit Fees Expense	15000	5000
Income Tax Consultancy Charges	4000	3500
RÖC Charges	8000	10000
Vat Expense	62207	-
Total	89207	18500



MECVIZ ENDOSCOPY (I) PRIVATE LIMITED

Notes Forming Part of the Statement of Profit & Loss as at 31st March, 2021

2.18 Earning Per Share

Particulars	31.03.2021	31.03.2020
	Amount	Amount
Profit After Tax	47064	-13853
Weighted average no. of equity shares outstanding	50000	50000
Basic and Diluted Earning Per Share (Rs.)	0.94128	-0.27706

2.19 Related Party Disclosure as on 31/03/2021

(i) List of Related Party

Name of Related Party	Relationship
Chetan M Joshi Parag S Dixit Pravin B Shetty Saurabha K.Bhatt Suryakant N.Chiplunkar Vijay S.Patil Vishal D. Chandekar Aprameya Engineering Ormed Systems	Key Management Personnel

(ii) Transaction during the year with Related Party

Nature of Transaction	31.03.2021	31.03.2020
	Amount	Amount
	Key Management Personnel	
Amount Paid	-	-
Amount Received	-	-
Remmuneration Paid	-	-

(iii) Balances as at 31/03/2021

Nature of Transaction	31.03.2021	31.03.2020
	Amount	Amount
	Key Management Personnel	
Balance of other Key Person		4384034
Balance of Ormad Systems	556854	
Balance of Aprameya Engineering	1000000	-



MECVIZ ENDOSCOPY (I) PRIVATE LIMITED

NOTES TO ACCOUNTS

1 SIGNIFICANT ACCOUNTING POLICY

A) BASIS OF ACCOUNTING AND PREPARATION OF FINANCIAL STATEMENTS

THE ACCOUNTS HAVE BEEN PREPARED ON THE HISTORICAL COST CONVENTION AND ON THE ACCOUNTING PRINCIPLES OF GOING CONCERN. ALL EXPENSES AND INCOME TO THE EXTENT ASCERTAINABLE WITH REASONABLE CERTAINTY, CONSIDERED PAYABLE AND RECEIVABLE RESPECTIVELY.

B) INVESTMENTS ARE VALUED AT COST. DIVIDEND AND INTEREST IF ANY IS ACCOUNTED FOR AS AND WHEN RECEIVED.

C) DEFERRED TAX IS RECOGNISED, SUBJECT TO CONSIDERATION OF PRUDENCE ON TIMING DIFFERENCES BETWEEN TAXABLE INCOME AND ACCOUNTING INCOME FOR THE PERIOD THAT IN ONE PERIOD AND ARE CAPABLE OF REVERSAL IN ONE OR MORE SUBSEQUENT PERIODS.

D) VALUTION OF STOCK:

RAW MATERIALS: AT COST
WORK IN PROCESS: AT COST
FINISHED GOODS: AT LOWER OF COST OR MARKET VALUE

2 IN THE OPINION OF THE BOARD, THE CURRENT ASSETS, LOANS AND ADVANCES WOULD IN THE ORDINARY COURSE OF BUSINESS REALISE THE AMOUNT STATED.

3 THE BALANCES OF SUNDRY DEBTORS, SUNDRY CREDITORS AND LOANS AND ADVANCES ARE SUBJECT TO CONFIRMATION. DUE ADJUSTMENT WILL BE MADE ON RECEIPTS THEIR OF IF NECESSARY.

4 REMMUNERETION TO AUDITOR:

PARTICULAR	2020-21	2019-20
AUDITOR REMMUNRETION	15000	5000

5 THE REMUNERATION TO DIRECTORS PAID/PROVIDED IN THE ACCOUNTS

PARTICULAR	2020-21	2019-20
DIRECTORS REMMUNERETION	-	-



6 EARNING PER SHARE

PARTICULAR	2020-21	2019-20
Net Profit after tax	55974	(13853)
No. of Equity share	50000	50000
Earning per share	1.12	(0.28)

7 RELATED PARTY DISCLOSER

AS PER THE ACCOUNTING STANDARD ON RELATED PARTY DISCLOSURE: (AS-18) ISSUED BY THE INSTITUTE OF CHARTERED ACCOUNTANTS OF INDIA, THE RELATED PARTIES OF THE COMPANY ARE AS FOLLOWS.

Name(s) of the related party and nature of relationship	Nature of contracts/arrangement/transactions	Duration of the contracts / arrangements/transactions	Salient terms of the contracts or arrangements or transactions including the value,	Date(s) of approval by the Board, if any:	Amount paid as advances, if any:
NIL					

AS PER REPORT OF EVEN DATE ATTACHED WITH

For, **JITENDRA A. PATEL & CO.**
CHARTERED ACCOUNTANTS

Jitendra A. Patel

(JITENDRA A. PATEL)
 PROPRIETOR
 M.NO:033543
 FRN : 104283W
 UDIN: 21033543AAAAFB6448

ON BEHALF OF THE BOARD OF DIRECTOR

Chetan Joshi
 DIRECTOR
 (CHETAN JOSHI)
 DIN:-03056083

Saurabh Bhatt
 DIRECTOR
 (SAURABH BHATT)
 DIN:-03071549

